3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Tumor-Agnostic
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
Classical hematology
1
CNS
1
Breast
1
Conditions
Thrombocytopenia
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
11
fludarabine phosphate
8
fludarabine
8
apixaban
8
Mycophenolic Acid
6
Melphalan
6
Busulfan
6
Whole-Body Irradiation
4
Tacrolimus
4
Rivaroxaban
4
Filgrastim
4
Biopsy
4
thymoglobulin
3
X-Rays
3
Specimen Handling
3
Rituximab
3
Peripheral Blood Stem Cell Transplantation
3
Hematopoietic Stem Cell Transplantation
3
Granulocyte Colony-Stimulating Factor
3
Enoxaparin
3
Bone Marrow Transplantation
3
Azacitidine
3
venetoclax
2
pegylated granulocyte colony-stimulating factor
2
olaparib
2
Tretinoin
2
Stem Cell Transplantation
2
Mesna
2
Injections
2
Heparin, Low-Molecular-Weight
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Tranexamic Acid
×
Classical hematology
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled